These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 34958499)
1. Recent advances in the diagnosis, classification and molecular pathogenesis of cutaneous mesenchymal neoplasms. Papke DJ; Hornick JL Histopathology; 2022 Jan; 80(1):216-232. PubMed ID: 34958499 [TBL] [Abstract][Full Text] [Related]
2. Gene fusions in superficial mesenchymal neoplasms: Emerging entities and useful diagnostic adjuncts. Fischer GM; Papke DJ Semin Diagn Pathol; 2023 Jul; 40(4):246-257. PubMed ID: 37156707 [TBL] [Abstract][Full Text] [Related]
3. [Fibrohistiocytic tumors of the skin: a heterogeneous group of superficially located mesenchymal neoplasms]. Mentzel T Pathologe; 2015 Feb; 36(1):79-88. PubMed ID: 25589356 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances? Hornick JL Mod Pathol; 2020 Jan; 33(Suppl 1):56-65. PubMed ID: 31653978 [TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669 [TBL] [Abstract][Full Text] [Related]
6. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma. Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939 [No Abstract] [Full Text] [Related]
7. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans. Wick MR; Ritter JH; Lind AC; Swanson PE Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848 [TBL] [Abstract][Full Text] [Related]
8. Cellular fibrous histiocytoma of the skin: evidence of a clonal process with different karyotype from dermatofibrosarcoma. Vanni R; Marras S; Faa G; Licheri S; Daniele GM; Fletcher CD Genes Chromosomes Cancer; 1997 Apr; 18(4):314-7. PubMed ID: 9087573 [TBL] [Abstract][Full Text] [Related]
9. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa. Cohen PR; Rapin RP; Farhood AI Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477 [No Abstract] [Full Text] [Related]
10. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Sandberg AA; Bridge JA Cancer Genet Cytogenet; 2003 Jan; 140(1):1-12. PubMed ID: 12550751 [No Abstract] [Full Text] [Related]
11. An update on selected cutaneous (myo) fibroblastic mesenchymal tumors. Georgantzoglou N; Linos K Semin Diagn Pathol; 2023 Jul; 40(4):295-305. PubMed ID: 37150655 [TBL] [Abstract][Full Text] [Related]
12. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors. Okita H; Ohtsuka T; Yamazaki S Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of ERG immunostaining in dermatofibroma. Yamada Y; Ichiki T; Susuki Y; Yamada-Nozaki Y; Tateishi Y; Furue M; Oda Y J Clin Pathol; 2023 Aug; 76(8):536-540. PubMed ID: 35318257 [TBL] [Abstract][Full Text] [Related]
14. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors. Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036 [TBL] [Abstract][Full Text] [Related]
15. Update on cutaneous mesenchymal tumors in the 5th edition of WHO classification of skin tumors with an emphasis on new fusion-associated neoplasms. Kalmykova AV; Baranovska-Andrigo V; Michal M Virchows Arch; 2024 Nov; 485(5):777-792. PubMed ID: 39264472 [TBL] [Abstract][Full Text] [Related]
16. Giant cell fibroblastoma in a child misdiagnosed as a dermatofibroma. Nguyen CM; Burch JM; Fitzpatrick JE; Peterson SL; Weston WL Pediatr Dermatol; 2002; 19(1):28-32. PubMed ID: 11860566 [TBL] [Abstract][Full Text] [Related]
17. Sarcomas--a clinicopathological guide with particular reference to cutaneous manifestation. I. Dermatofibrosarcoma protuberans, malignant fibrous histiocytoma and the epithelioid sarcoma of Enzinger. Fletcher CD; McKee PH Clin Exp Dermatol; 1984 Sep; 9(5):451-65. PubMed ID: 6091955 [No Abstract] [Full Text] [Related]
18. Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms. Costigan DC; Doyle LA Histopathology; 2016 May; 68(6):776-95. PubMed ID: 26763770 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous and subcutaneous fibrohistiocytic tumors of intermediate malignancy: an update. Billings SD; Folpe AL Am J Dermatopathol; 2004 Apr; 26(2):141-55. PubMed ID: 15024197 [TBL] [Abstract][Full Text] [Related]
20. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall. Abdaljaleel MY; North JP Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]